Literature DB >> 24190587

Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.

Mark A Wetherell1, Catharine Montgomery.   

Abstract

RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction. While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users.
OBJECTIVES: The current study is the first to explore the effects of ecstasy-polydrug use on psychological distress and basal functioning of the HPA axis through assessing the secretion of cortisol across the diurnal period.
METHOD: Seventy-six participants (21 nonusers, 29 light ecstasy-polydrug users, 26 heavy ecstasy-polydrug users) completed a substance use inventory and measures of psychological distress at baseline, then two consecutive days of cortisol sampling (on awakening, 30 min post awakening, between 1400 and 1600 hours and pre bedtime). On day 2, participants also attended the laboratory to complete a 20-min multitasking stressor.
RESULTS: Both user groups exhibited significantly greater levels of anxiety and depression than nonusers. On day 1, all participants exhibited a typical cortisol profile, though light users had significantly elevated levels pre-bed. On day 2, heavy users demonstrated elevated levels upon awakening and all ecstasy-polydrug users demonstrated elevated pre-bed levels compared to non-users. Significant between group differences were also observed in afternoon cortisol levels and in overall cortisol secretion across the day.
CONCLUSIONS: The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24190587     DOI: 10.1007/s00213-013-3325-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  74 in total

Review 1.  Co-morbidity of personality disorders in individuals with substance use disorders.

Authors:  R Verheul
Journal:  Eur Psychiatry       Date:  2001-08       Impact factor: 5.361

2.  If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans.

Authors:  Gregory E Miller; Edith Chen; Eric S Zhou
Journal:  Psychol Bull       Date:  2007-01       Impact factor: 17.737

3.  Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.

Authors:  A C Parrott; T Buchanan; A B Scholey; T Heffernan; J Ling; J Rodgers
Journal:  Hum Psychopharmacol       Date:  2002-08       Impact factor: 1.672

4.  Reply to 'MDMA can increase cortical levels by 800% in dance clubbers' Parrott et al.

Authors:  K Wolff; Kj Aitchison
Journal:  J Psychopharmacol       Date:  2013-01       Impact factor: 4.153

5.  Electrophysiological indices of response inhibition in human polydrug users.

Authors:  C A Roberts; S Fairclough; J E Fisk; F T Tames; C Montgomery
Journal:  J Psychopharmacol       Date:  2013-06-25       Impact factor: 4.153

6.  MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.

Authors:  J L Reay; C Hamilton; D O Kennedy; A B Scholey
Journal:  J Psychopharmacol       Date:  2006-05       Impact factor: 4.153

7.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

8.  MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study.

Authors:  Andrew C Parrott; Amy Gibbs; Andrew B Scholey; Rebecca King; Katherine Owens; Phil Swann; Ed Ogden; Con Stough
Journal:  Psychopharmacology (Berl)       Date:  2011-02-12       Impact factor: 4.530

9.  Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans.

Authors:  Roberta Pacifici; Piergiorgio Zuccaro; Magí Farré; Sandra Poudevida; Sergio Abanades; Simona Pichini; Klaus Langohr; Jordi Segura; Rafael de la Torre
Journal:  Addiction       Date:  2007-06       Impact factor: 6.526

10.  Components of the diurnal cortisol cycle in relation to upper respiratory symptoms and perceived stress.

Authors:  Sue Edwards; Frank Hucklebridge; Angela Clow; Phil Evans
Journal:  Psychosom Med       Date:  2003 Mar-Apr       Impact factor: 4.312

View more
  4 in total

1.  Zinc attenuates ecstasy-induced apoptosis through downregulation of caspase-3 in cultured TM3 cells: An experimental study.

Authors:  Marziyeh Lozeie; Morteza Bagheri; Isa Abdi Rad; Nadia Hossein-Zadeh; Mahdyieh Nasir-Zadeh
Journal:  Int J Reprod Biomed       Date:  2020-09-20

2.  Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders.

Authors:  Shareefa Dalvie; Chiara Fabbri; Raj Ramesar; Alessandro Serretti; Dan J Stein
Journal:  Metab Brain Dis       Date:  2015-11-12       Impact factor: 3.584

3.  Meta-analysis of executive functioning in ecstasy/polydrug users.

Authors:  C A Roberts; A Jones; C Montgomery
Journal:  Psychol Med       Date:  2016-03-11       Impact factor: 7.723

Review 4.  Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs.

Authors:  Andrew C Parrott
Journal:  Brain Sci       Date:  2018-03-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.